Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?

Table 1 Comparison of changes in AMH values over time between groups

	Group 1 (Sh)	Group 2 (CP + Saline)	Group 3 (CP + M)	Group 4 (M)	Group 5 (S)	p^*
AMH basal	8.5 ± 0.7	8.3 ± 0.5^e	8.3 ± 0.9	8.5 ± 0.7	8.4 ± 0.5	> 0.05
AMH 15th day	8.7 ± 1.0	8.3 ± 0.8^e	8.6 ± 1.0	8.8 ± 1.0	8.6 ± 0.9	> 0.05
AMH 28th day	8.7 ± 0.8^a	5.3 ± 1.0^a,b,c,d,e	7.0 ± 1.4^b	8.0 ± 0.9^c	8.3 ± 0.9^d	< 0.001
^*p	> 0.05	< 0.001	> 0.05	> 0.05	> 0.05

Note.^*p = One-way ANOVA test with Bonferroni correction. (a) difference between Group 1 and Group 2, p < 0.001; (b) difference between Group 2 and Group 3, p < 0.01; (c) difference between Group 2 and Group 4, p < 0.001; (d) difference between Group 2 and Group 5, p < 0.001; (e) difference between basal and mid AMH and last AMH in Group 2, both p < 0.001

ISSN: 1757-2215